{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T22:21:07Z","timestamp":1788992467126,"version":"build-2803163510"},"reference-count":70,"publisher":"MDPI AG","issue":"9","license":[{"start":{"date-parts":[[2022,5,3]],"date-time":"2022-05-03T00:00:00Z","timestamp":1651536000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Programme de Recherche Translationnelle INCa","award":["PRTK N\u00b0PRT-K-20-107"],"award-info":[{"award-number":["PRTK N\u00b0PRT-K-20-107"]}]},{"name":"Programme de Recherche Translationnelle INCa","award":["CA016672"],"award-info":[{"award-number":["CA016672"]}]},{"name":"Programme de Recherche Translationnelle INCa","award":["CA100632"],"award-info":[{"award-number":["CA100632"]}]},{"name":"MD Anderson Cancer Centre Support Grant (CCSG)","award":["PRTK N\u00b0PRT-K-20-107"],"award-info":[{"award-number":["PRTK N\u00b0PRT-K-20-107"]}]},{"name":"MD Anderson Cancer Centre Support Grant (CCSG)","award":["CA016672"],"award-info":[{"award-number":["CA016672"]}]},{"name":"MD Anderson Cancer Centre Support Grant (CCSG)","award":["CA100632"],"award-info":[{"award-number":["CA100632"]}]},{"name":"MD Anderson Cancer Center Leukemia SPORE","award":["PRTK N\u00b0PRT-K-20-107"],"award-info":[{"award-number":["PRTK N\u00b0PRT-K-20-107"]}]},{"name":"MD Anderson Cancer Center Leukemia SPORE","award":["CA016672"],"award-info":[{"award-number":["CA016672"]}]},{"name":"MD Anderson Cancer Center Leukemia SPORE","award":["CA100632"],"award-info":[{"award-number":["CA100632"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancers"],"abstract":"<jats:p>Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is a rare and aggressive leukemia derived from plasmacytoid dendritic cells (pDCs). It is associated with a remarkably poor prognosis and unmet need for better therapies. Recently, the first-in-class CD123-targeting therapy, tagraxofusp, was approved for treatment of BPDCN. Other CD123-targeting strategies are in development, including bispecific antibodies and combination approaches with tagraxofusp and other novel agents. In other blood cancers, adoptive T-cell therapy using chimeric antigen receptor (CAR)-modified T cells represents a promising new avenue in immunotherapy, showing durable remissions in some relapsed hematologic malignancies. Here, we report on novel and innovative therapies in development to target surface molecules in BPDCN currently in clinical trials or in preclinical stages. We also discuss new cell surface targets that may have implications for future BPDCN treatment.<\/jats:p>","DOI":"10.3390\/cancers14092287","type":"journal-article","created":{"date-parts":[[2022,5,4]],"date-time":"2022-05-04T08:21:25Z","timestamp":1651652485000},"page":"2287","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["CD123 and More: How to Target the Cell Surface of Blastic Plasmacytoid Dendritic Cell Neoplasm"],"prefix":"10.3390","volume":"14","author":[{"given":"Elodie","family":"B\u00f4le-Richard","sequence":"first","affiliation":[{"name":"INSERM, EFS BFC, UMR1098, RIGHT, University of Bourgogne Franche-Comt\u00e9, Interactions Greffon-H\u00f4te-Tumeur\/Ing\u00e9nierie Cellulaire et G\u00e9nique, F-25000 Besancon, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1670-6513","authenticated-orcid":false,"given":"Naveen","family":"Pemmaraju","sequence":"additional","affiliation":[{"name":"Department of Leukemia, University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Blandine","family":"Ca\u00ebl","sequence":"additional","affiliation":[{"name":"INSERM, EFS BFC, UMR1098, RIGHT, University of Bourgogne Franche-Comt\u00e9, Interactions Greffon-H\u00f4te-Tumeur\/Ing\u00e9nierie Cellulaire et G\u00e9nique, F-25000 Besancon, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Etienne","family":"Daguindau","sequence":"additional","affiliation":[{"name":"INSERM, EFS BFC, UMR1098, RIGHT, University of Bourgogne Franche-Comt\u00e9, Interactions Greffon-H\u00f4te-Tumeur\/Ing\u00e9nierie Cellulaire et G\u00e9nique, F-25000 Besancon, France"},{"name":"Service H\u00e9matologie, CHU Besan\u00e7on, F-25000 Besancon, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew A.","family":"Lane","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA 02215, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2022,5,3]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"1628","DOI":"10.1056\/NEJMoa1815105","article-title":"Tagraxofusp in Blastic Plasmacytoid Dendritic-Cell Neoplasm","volume":"380","author":"Pemmaraju","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1158\/2159-8290.CD-16-0999","article-title":"Blastic Plasmacytoid Dendritic Cell Neoplasm Is Dependent on BCL2 and Sensitive to Venetoclax","volume":"7","author":"Montero","year":"2017","journal-title":"Cancer Discov."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"1861","DOI":"10.3324\/haematol.2017.169326","article-title":"Bortezomib as a New Therapeutic Approach for Blastic Plasmacytoid Dendritic Cell Neoplasm","volume":"102","author":"Philippe","year":"2017","journal-title":"Haematologica"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1002\/hon.2671","article-title":"The Lenalidomide\/Bortezomib\/Dexamethasone Regimen for the Treatment of Blastic Plasmacytoid Dendritic Cell Neoplasm","volume":"37","author":"Marmouset","year":"2019","journal-title":"Hematol. Oncol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"1606","DOI":"10.1038\/leu.2014.64","article-title":"Molecular Profiling of Blastic Plasmacytoid Dendritic Cell Neoplasm Reveals a Unique Pattern and Suggests Selective Sensitivity to NF-KB Pathway Inhibition","volume":"28","author":"Sapienza","year":"2014","journal-title":"Leukemia"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"4238","DOI":"10.1182\/bloodadvances.2019000647","article-title":"How Should We Diagnose and Treat Blastic Plasmacytoid Dendritic Cell Neoplasm Patients?","volume":"3","author":"Vidal","year":"2019","journal-title":"Blood Adv."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1111\/j.1365-2133.2009.09373.x","article-title":"Blastic Plasmacytoid Dendritic Cell Neoplasm: Is Transplantation the Treatment of Choice?","volume":"162","author":"Dalle","year":"2010","journal-title":"Br. J. Dermatol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1111\/bjh.14146","article-title":"Blastic Plasmacytoid Dendritic Cell Neoplasm: Diagnostic Criteria and Therapeutical Approaches","volume":"174","author":"Pagano","year":"2016","journal-title":"Br. J. Haematol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1182\/blood-2012-08-448613","article-title":"Stem Cell Transplantation Can Provide Durable Disease Control in Blastic Plasmacytoid Dendritic Cell Neoplasm: A Retrospective Study from the European Group for Blood and Marrow Transplantation","volume":"121","author":"Dietrich","year":"2013","journal-title":"Blood"},{"key":"ref_10","first-page":"51","article-title":"Allogeneic Hematopoietic Cell Transplantation for Patients with Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)","volume":"7","author":"Bashir","year":"2021","journal-title":"Bone Marrow Transpl."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"1565","DOI":"10.1126\/science.1203486","article-title":"Cancer Immunoediting: Integrating Immunity\u2019s Roles in Cancer Suppression and Promotion","volume":"331","author":"Schreiber","year":"2011","journal-title":"Science"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"1432","DOI":"10.1126\/science.342.6165.1432","article-title":"Cancer Immunotherapy","volume":"342","year":"2013","journal-title":"Science"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"6938","DOI":"10.4049\/jimmunol.0901766","article-title":"The Optimal Antigen Response of Chimeric Antigen Receptors Harboring the CD3\u03b6 Transmembrane Domain Is Dependent upon Incorporation of the Receptor into the Endogenous TCR\/CD3 Complex","volume":"184","author":"Bridgeman","year":"2010","journal-title":"J. Immunol."},{"key":"ref_14","first-page":"401","article-title":"Transfer of Chimeric Receptor Gene Made of Variable Regions of Tumor-Specific Antibody Confers Anticarbohydrate Specificity on T Cells","volume":"5","author":"Mezzanzanica","year":"1998","journal-title":"Cancer Gene Ther."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1016\/0092-8674(89)90943-4","article-title":"Expression of a Hybrid Immunoglobulin-T Cell Receptor Protein in Transgenic Mice","volume":"58","author":"Becker","year":"1989","journal-title":"Cell"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1016\/0092-8674(90)90341-B","article-title":"Chimeric Immunoglobulin-T Cell Receptor Proteins Form Functional Receptors: Implications for T Cell Receptor Complex Formation and Activation","volume":"60","author":"Goverman","year":"1990","journal-title":"Cell"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"10024","DOI":"10.1073\/pnas.86.24.10024","article-title":"Expression of Immunoglobulin-T-Cell Receptor Chimeric Molecules as Functional Receptors with Antibody-Type Specificity","volume":"86","author":"Gross","year":"1989","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"960","DOI":"10.1016\/0006-291X(87)90502-X","article-title":"Expression of Chimeric Receptor Composed of Immunoglobulin-Derived V Regions and T-Cell Receptor-Derived C Regions","volume":"149","author":"Kuwana","year":"1987","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"720","DOI":"10.1073\/pnas.90.2.720","article-title":"Specific Activation and Targeting of Cytotoxic Lymphocytes through Chimeric Single Chains Consisting of Antibody-Binding Domains and the Gamma or Zeta Subunits of the Immunoglobulin and T-Cell Receptors","volume":"90","author":"Eshhar","year":"1993","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1007\/BF00820666","article-title":"The T-Body Approach: Potential for Cancer Immunotherapy","volume":"18","author":"Eshhar","year":"1996","journal-title":"Springer Semin. Immunopathol."},{"key":"ref_21","first-page":"3369","article-title":"In Vivo Antitumor Activity of T Cells Redirected with Chimeric Antibody\/T-Cell Receptor Genes","volume":"55","author":"Hwu","year":"1995","journal-title":"Cancer Res."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1517\/14712598.2011.573476","article-title":"Chimeric Antigen Receptor (CAR)-Engineered Lymphocytes for Cancer Therapy","volume":"11","author":"Ramos","year":"2011","journal-title":"Expert Opin. Biol. Ther."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1158\/2159-8290.CD-12-0548","article-title":"The Basic Principles of Chimeric Antigen Receptor (CAR) Design","volume":"3","author":"Sadelain","year":"2013","journal-title":"Cancer Discov."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"712","DOI":"10.1089\/hum.2007.028","article-title":"Optimizing Adoptive Polyclonal T Cell Immunotherapy of Lymphomas, Using a Chimeric T Cell Receptor Possessing CD28 and CD137 Costimulatory Domains","volume":"18","author":"Wang","year":"2007","journal-title":"Hum. Gene Ther."},{"key":"ref_25","doi-asserted-by":"crossref","unstructured":"Stoiber, S., Cadilha, B.L., Benmebarek, M.-R., Lesch, S., Endres, S., and Kobold, S. (2019). Limitations in the Design of Chimeric Antigen Receptors for Cancer Therapy. Cells, 8.","DOI":"10.3390\/cells8050472"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.celrep.2017.09.015","article-title":"Tonic 4-1BB Costimulation in Chimeric Antigen Receptors Impedes T Cell Survival and Is Vector Dependent","volume":"21","author":"Mukherjee","year":"2017","journal-title":"Cell Rep."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"223","DOI":"10.3324\/haematol.2014.111740","article-title":"In Vivo and in Vitro Sensitivity of Blastic Plasmacytoid Dendritic Cell Neoplasm to SL-401, an Interleukin-3 Receptor Targeted Biologic Agent","volume":"100","author":"Roggy","year":"2015","journal-title":"Haematologica"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1111\/j.1365-2141.2009.07679.x","article-title":"Extended Diagnostic Criteria for Plasmacytoid Dendritic Cell Leukaemia","volume":"145","author":"Feuillard","year":"2009","journal-title":"Br. J. Haematol."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1186\/2050-7771-2-4","article-title":"CD 123 Is a Membrane Biomarker and a Therapeutic Target in Hematologic Malignancies","volume":"2","author":"Testa","year":"2014","journal-title":"Biomark Res."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1080\/10428190701799035","article-title":"Phase I Clinical Study of Diphtheria Toxin-Interleukin 3 Fusion Protein in Patients with Acute Myeloid Leukemia and Myelodysplasia","volume":"49","author":"Frankel","year":"2008","journal-title":"Leuk. Lymphoma"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1182\/blood-2014-06-578633","article-title":"Targeted Diphtheria Toxin to Treat BPDCN","volume":"124","author":"FitzGerald","year":"2014","journal-title":"Blood"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1182\/blood-2014-04-566737","article-title":"Activity of SL-401, a Targeted Therapy Directed to Interleukin-3 Receptor, in Blastic Plasmacytoid Dendritic Cell Neoplasm Patients","volume":"124","author":"Frankel","year":"2014","journal-title":"Blood"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"4020","DOI":"10.1182\/bloodadvances.2019000173","article-title":"Approval of Tagraxofusp-Erzs for Blastic Plasmacytoid Dendritic Cell Neoplasm","volume":"4","author":"Pemmaraju","year":"2020","journal-title":"Blood Adv."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1016\/j.clml.2021.05.018","article-title":"Novel Therapeutic Approaches in Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN): Era of Targeted Therapy","volume":"21","author":"Wilson","year":"2021","journal-title":"Clin. Lymphoma Myeloma Leuk."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"2568","DOI":"10.1080\/10428194.2021.1927021","article-title":"Targeting CD123 in Hematologic Malignancies: Identifying Suitable Patients for Targeted Therapy","volume":"62","author":"Patnaik","year":"2021","journal-title":"Leuk. Lymphoma"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"S67","DOI":"10.1016\/S2152-2650(20)30466-3","article-title":"Targeting CD123 in AML","volume":"20","author":"Lane","year":"2020","journal-title":"Clin. Lymphoma Myeloma Leuk."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"2346","DOI":"10.1182\/blood-2021-147486","article-title":"Safety and Efficacy of Combining Tagraxofusp (SL-401) with Azacitidine or Azacitidine and Venetoclax in a Phase 1b Study for CD123 Positive AML, MDS, or BPDCN","volume":"138","author":"Lane","year":"2021","journal-title":"Blood"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"1406","DOI":"10.3109\/10428194.2014.956316","article-title":"A Phase 1 Study of the Safety, Pharmacokinetics and Anti-Leukemic Activity of the Anti-CD123 Monoclonal Antibody CSL360 in Relapsed, Refractory or High-Risk Acute Myeloid Leukemia","volume":"56","author":"He","year":"2015","journal-title":"Leuk. Lymphoma"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1158\/1535-7163.MCT-17-0742","article-title":"Characterization of SGN-CD123A, A Potent CD123-Directed Antibody\u2013Drug Conjugate for Acute Myeloid Leukemia","volume":"17","author":"Li","year":"2018","journal-title":"Mol. Cancer Ther."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"1211","DOI":"10.1021\/acsmedchemlett.9b00254","article-title":"Synthesis of Highly Potent N-10 Amino-Linked DNA-Alkylating Indolinobenzodiazepine Antibody\u2013Drug Conjugates (ADCs)","volume":"10","author":"Archer","year":"2019","journal-title":"ACS Med. Chem. Lett."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"1271","DOI":"10.1158\/1535-7163.MCT-17-1077","article-title":"IMGN779, a Novel CD33-Targeting Antibody\u2013Drug Conjugate with DNA-Alkylating Activity, Exhibits Potent Antitumor Activity in Models of AML","volume":"17","author":"Kovtun","year":"2018","journal-title":"Mol. Cancer Ther."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"848","DOI":"10.1182\/bloodadvances.2018017517","article-title":"A CD123-Targeting Antibody-Drug Conjugate, IMGN632, Designed to Eradicate AML While Sparing Normal Bone Marrow Cells","volume":"2","author":"Kovtun","year":"2018","journal-title":"Blood Adv."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1182\/blood-2020-139903","article-title":"Clinical Profile of IMGN632, a Novel CD123-Targeting Antibody-Drug Conjugate (ADC), in Patients with Relapsed\/Refractory (R\/R) Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)","volume":"136","author":"Pemmaraju","year":"2020","journal-title":"Blood"},{"key":"ref_44","doi-asserted-by":"crossref","unstructured":"Allen, C., Zeidan, A.M., and Bewersdorf, J.P. (2021). BiTEs, DARTS, BiKEs and TriKEs\u2014Are Antibody Based Therapies Changing the Future Treatment of AML?. Life, 11.","DOI":"10.3390\/life11060465"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1182\/blood.2020007732","article-title":"Flotetuzumab as Salvage Immunotherapy for Refractory Acute Myeloid Leukemia","volume":"137","author":"Uy","year":"2021","journal-title":"Blood"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1182\/blood-2018-99-119786","article-title":"Complete Responses in Relapsed\/Refractory Acute Myeloid Leukemia (AML) Patients on a Weekly Dosing Schedule of XmAb14045, a CD123 x CD3 T Cell-Engaging Bispecific Antibody: Initial Results of a Phase 1 Study","volume":"132","author":"Ravandi","year":"2018","journal-title":"Blood"},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1182\/blood-2020-141619","article-title":"Preliminary Results from a Phase 1 Study of APVO436, a Novel Anti-CD123 x Anti-CD3 Bispecific Molecule, in Relapsed\/Refractory Acute Myeloid Leukemia and Myelodysplastic Syndrome","volume":"136","author":"Watts","year":"2020","journal-title":"Blood"},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"177ra38","DOI":"10.1126\/scitranslmed.3005930","article-title":"CD19-Targeted T Cells Rapidly Induce Molecular Remissions in Adults with Chemotherapy-Refractory Acute Lymphoblastic Leukemia","volume":"5","author":"Brentjens","year":"2013","journal-title":"Sci. Transl. Med."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"224ra25","DOI":"10.1126\/scitranslmed.3008226","article-title":"Efficacy and Toxicity Management of 19-28z CAR T Cell Therapy in B Cell Acute Lymphoblastic Leukemia","volume":"6","author":"Davila","year":"2014","journal-title":"Sci. Transl. Med."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"1509","DOI":"10.1056\/NEJMoa1215134","article-title":"Chimeric Antigen Receptor\u2013Modified T Cells for Acute Lymphoid Leukemia","volume":"368","author":"Grupp","year":"2013","journal-title":"New Engl. J. Med."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1200\/JCO.2014.56.2025","article-title":"Chemotherapy-Refractory Diffuse Large B-Cell Lymphoma and Indolent B-Cell Malignancies Can Be Effectively Treated With Autologous T Cells Expressing an Anti-CD19 Chimeric Antigen Receptor","volume":"33","author":"Kochenderfer","year":"2015","journal-title":"J. Clin. Oncol."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"3392","DOI":"10.1172\/JCI80010","article-title":"CAR Therapy: The CD19 Paradigm","volume":"125","author":"Sadelain","year":"2015","journal-title":"J. Clin. Investig."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1056\/NEJMoa1709866","article-title":"Tisagenlecleucel in Children and Young Adults with B-Cell Lymphoblastic Leukemia","volume":"378","author":"Maude","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"3138","DOI":"10.1182\/blood-2012-12-474056","article-title":"T Cells Expressing CD123-Specific Chimeric Antigen Receptors Exhibit Specific Cytolytic Effector Functions and Antitumor Effects against Human Acute Myeloid Leukemia","volume":"122","author":"Mardiros","year":"2013","journal-title":"Blood"},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"2343","DOI":"10.1182\/blood-2013-09-529537","article-title":"Preclinical Targeting of Human Acute Myeloid Leukemia and Myeloablation Using Chimeric Antigen Receptor\u2013Modified T Cells","volume":"123","author":"Gill","year":"2014","journal-title":"Blood"},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"2395","DOI":"10.1182\/blood-2016-08-736041","article-title":"Optimized Depletion of Chimeric Antigen Receptor T Cells in Murine Xenograft Models of Human Acute Myeloid Leukemia","volume":"129","author":"Tasian","year":"2017","journal-title":"Blood"},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"3228","DOI":"10.1038\/s41375-020-0777-1","article-title":"CD28\/4-1BB CD123 CAR T Cells in Blastic Plasmacytoid Dendritic Cell Neoplasm","volume":"34","author":"Fredon","year":"2020","journal-title":"Leukemia"},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1016\/j.omto.2020.04.009","article-title":"Rapidly Switchable Universal CAR-T Cells for Treatment of CD123-Positive Leukemia","volume":"17","author":"Loff","year":"2020","journal-title":"Mol. Ther. Oncolytics."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"4039","DOI":"10.1182\/blood.V128.22.4039.4039","article-title":"Pre-Clinical Studies of Anti-CD123 CAR-T Cells for the Treatment of Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)","volume":"128","author":"Cai","year":"2016","journal-title":"Blood"},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1016\/j.omtm.2020.06.024","article-title":"The Art and Science of Selecting a CD123-Specific Chimeric Antigen Receptor for Clinical Testing","volume":"18","author":"Riberdy","year":"2020","journal-title":"Mol. Ther.\u2014Methods Clin. Dev."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"3145","DOI":"10.1182\/blood.2020009759","article-title":"Proof of Concept for a Rapidly Switchable Universal CAR-T Platform with UniCAR-T-CD123 in Relapsed\/Refractory AML","volume":"137","author":"Wermke","year":"2021","journal-title":"Blood"},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1002\/ajh.24258","article-title":"Blastic Plasmacytoid Dendritic Cell Neoplasm with Leukemic Presentation: 10-Color Flow Cytometry Diagnosis and HyperCVAD Therapy","volume":"91","author":"Deotare","year":"2016","journal-title":"Am. J. Hematol."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"e432","DOI":"10.3324\/haematol.2018.214635","article-title":"Daratumumab for Treatment of Blastic Plasmacytoid Dendritic Cell Neoplasm. A Single-Case Report","volume":"104","author":"Iversen","year":"2019","journal-title":"Haematologica"},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"3039","DOI":"10.1080\/10428194.2021.1941938","article-title":"Daratumumab-Based Therapy after Prior Azacytidine-Venetoclax in an Octagenerian Female with BPDCN (Blastic Plasmacytoid Dendritic Cell Neoplasm)\u2014A New Perspective","volume":"62","author":"Mirgh","year":"2021","journal-title":"Leuk. Lymphoma"},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"477","DOI":"10.3324\/haematol.2010.025916","article-title":"Optimization of the HA-1-Specific T-Cell Receptor for Gene Therapy of Hematologic Malignancies","volume":"96","author":"Hagedoorn","year":"2011","journal-title":"Haematologica"},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"1804","DOI":"10.3389\/fimmu.2020.01804","article-title":"HA-1H T-Cell Receptor Gene Transfer to Redirect Virus-Specific T Cells for Treatment of Hematological Malignancies After Allogeneic Stem Cell Transplantation: A Phase 1 Clinical Study","volume":"11","author":"Jedema","year":"2020","journal-title":"Front. Immunol."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1111\/bjd.20770","article-title":"Adcitmer\u00ae, a New CD56-Targeting Monomethyl Auristatin E-Conjugated Antibody, Is a Potential Therapeutic Approach in Merkel Cell Carcinoma","volume":"186","author":"Esnault","year":"2021","journal-title":"Br. J. Dermatol."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"3686","DOI":"10.1038\/s41388-018-0187-2","article-title":"Antitumor Activity of CD56-Chimeric Antigen Receptor T Cells in Neuroblastoma and SCLC Models","volume":"37","author":"Crossland","year":"2018","journal-title":"Oncogene"},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1016\/j.humimm.2009.03.004","article-title":"Immunoglobulin-like Transcript 3: A Crucial Regulator of Dendritic Cell Function","volume":"70","author":"Vlad","year":"2009","journal-title":"Hum. Immunol."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"2487","DOI":"10.1016\/j.ymthe.2018.08.001","article-title":"A Novel Anti-LILRB4 CAR-T Cell for the Treatment of Monocytic AML","volume":"26","author":"John","year":"2018","journal-title":"Mol. Ther."}],"container-title":["Cancers"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2072-6694\/14\/9\/2287\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T23:05:48Z","timestamp":1760137548000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2072-6694\/14\/9\/2287"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,5,3]]},"references-count":70,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2022,5]]}},"alternative-id":["cancers14092287"],"URL":"https:\/\/doi.org\/10.3390\/cancers14092287","relation":{},"ISSN":["2072-6694"],"issn-type":[{"value":"2072-6694","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,5,3]]}}}